哮喘和肺心病血浆溶血血小板激活因子测定

Bioassay of Lyso Platelet Activiting Factor and Its Changes in Bronchial Asthma and Chronic Pulmonary Heart Disease

对２０例哮喘（发作组１２例，缓解组８例），１０例肺心病及１０例正常人进行了血浆溶血血小板激活因子（ｌｙｓｏ－ｐｌａｔｅｌｅｔａｃｔｉｖａｔｉｎｇｆａｃｔｏｒ，ｌｙｓｏ－ＰＡＦ）生物定量测定，并加以比较。结果显示哮喘发作组ｌｙｓｏ－ＰＡＦ含量较哮喘缓解组，肺心病组，正常组有非常显著升高。哮喘缓解组）ｌｙｓｏ－ＰＡＦ含量明显高于正常组。肺心病组ｌｙｓｏ－ＰＡＦ含量较正常组显著升高，其中ＰａＣＯ２＞６．６７ｋＰａ组的ｌｙｓｏ－ＰＡＦ含量明显高于ＰａＣＯ２＜６．６７地组。本文提示ＰＡＦ作为一种强有力的炎性解质，在呼吸道慢性炎症，肺心病，尤其是哮喘的发作和气道高反应性的形成过程中起着重要作用，并为治疗方面提出了新观点。

Plasma lyso platelet activating factor (lyso-PAF)was determined by bioassay in 20 cases of bronchial asthma(12 of them in episode, Gnoup A and 8 in remission, Group B,10 cases of chronic pulmonary heart disease (CPHD,Group C), and 10normal individuals as control(Group D).Results showed that the lyso-PAF levels were increased most significantly in Group A, that a more increase in Group B and Group C than in Group D, and that within Group C those having PaCO_2>6.67kpa had a higher level than those with PaCO_2<6.67kPa.It was suggested that lyso-PAF may play an important role in the development of chronic respiratory tract inflammation,CPHD,and especially bronchial asthma and airway hyperactivity as a potent inflammatory mediator,thereby providing a new insight into the treatment.